WikiMD is the world's largest medical encyclopedia with
13,592 pages, 4,139,098 edits & 37,811,477 views.
Sonidegib
Sonidegib (INN) or erismodegib (USAN), also known as LDE225, is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis.[1][2] It has been investigated as a potential treatment for:
- Pancreatic cancer[3][4][5][6]
- Breast cancer[7][8]
- Basal cell carcinoma of the skin[9][10][11]
- Small cell lung cancer[12]
- Medulloblastoma[13][14]
- Advanced solid tumours (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme)[15][16][17]
- Acute leukaemia[18]
- Chronic myeloid leukaemia[19]
- Myelofibrosis and essential thrombocythaemia[20]
It has demonstrated significant efficacy against melanoma in vitro and in vivo.[21] It also demonstrated efficacy in a mouse model of pancreatic cancer.[22]
Reference list
Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ
Learn more about Sonidegib
- Dailymed label info
- Scientific articles
- Drug portal Sonidegib
- toxicity info on Sonidegib
- FDA Sonidegib
Latest research - Sonidegib
External links
This WikiMD article Sonidegib is a stub. If you are familiar with the topic Sonidegib, you can help us. Paid editors welcome!
Sonidegib is part of WikiMD's free ^articles!
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
 Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available |
